Pancreatic Cancer
ABI-007 for Metastatic Adenocarcinoma of the Pancreas (FHCRC-2350)
A Randomized Phase III Study of Weekly ABI-007 (Abraxane) plus Gemcitabine (Gemzar) versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas
Investigator: Sunil Hingorani, MD, PhD; Conditions: Pancreatic Cancer; Status: Closed; Study ID: NCT00844649
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Investigator: Andrew Coveler, MD; Conditions: Pancreatic Neoplasms; Status: Closed; Study ID: NCT01166490
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
Investigator: Andrew Coveler, MD; Conditions: Neoplasms, Neoplasm Metastasis, Pancreatic Cancer; Status: Recruiting; Study ID: NCT01373164
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Investigator: Dr. Celestia S. Higano; Conditions: Advanced Solid Tumors; Status: Closed; Study ID: NCT00940225
Join Us On